4 Biotech Stocks That Could Break Through the Market

Four TSX biotech stocks could deliver outsized gains in 2023, as they are poised to break through the market soon.

| More on:
Workers use a microscope to do medical research in a modern laboratory.

Source: Getty Images

Most biotech stocks have low visibility with investors because the risks are pretty high. Nonetheless, the TSX has several names worth watching in 2023. Bausch Health (TSX:BHC) has appreciated substantially from year-end 2022, and three more could break through the market soon.

You can consider taking positions in BELLUS Health (TSX:BLU), Fennec Pharmaceuticals (TSX:FRX), or Knight Therapeutics (TSX:GUD) while the stock prices are low.

Strong upward momentum

Despite poor market conditions and a challenging macro environment, Bausch Health continues to display strong momentum. At $12.46 per share, the trailing one-year price return is -59.11%. However, the biotech stock beat the market year to date at +46.59% versus +6.17%.

The $4.51 billion specialty pharmaceutical company is a spin-off of Bausch & Lomb’s eyecare business. Bausch Health also incorporates various businesses focused on gastroenterology, neurology, dermatology, and international pharmaceuticals.

Management believes its leading durable brands and core business segments are growth drivers that will help advance global health.

Game changer

BELLUS Health is advancing a potential solution for refractory chronic cough called Camlipixant, or BLU-5937. This lead product candidate could be the game-changer for this $1.3 billion drug development company. The healthcare stock trades at $10.39 (-6.23% year to date) but could soar through the roof once BLU-5937 obtains approval for commercialization.

According to management, BELLUS has initiated the CALM Phase 3 clinical program for refractory chronic cough. Two trials (CALM-1 and CALM-2) to evaluate the efficacy, safety, and tolerability of Camlipixant are running concurrently. The development program is critical as the future of treating cough rests with the company.

Important breakthrough

Fennec Pharmaceuticals focuses on children with cancer and experiencing hearing loss due to the effect of chemotherapy. The $326.42 million commercial-stage specialty pharmaceutical company develops PEDMARK, which is devoted to fighting ototoxicity in pediatric cancer patients who receive cisplatin-based chemotherapy.

The sodium thiosulfate injection is the first and only Food and Drug Administration (FDA)-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumours. On January 31, 2023, the U.S. FDA granted Orphan Drug Exclusivity to PEDMARK.

Rosty Raykov, Fennec’s chief executive officer, said the approval represents an important breakthrough treatment option for the pediatric cancer community.” The stock is down 5.04% year to date ($12.43 per share), although the one-year price return is 73.85%.

Unique platform

Knight Therapeutics focuses on acquiring or in-licensing innovative pharmaceutical products for the home country and Latin America. Moreover, it acquires mature or “under-promoted” products from Big Pharma and licenses late-stage products.

The $583.46 million multinational specialty pharmaceutical company operates in Pan America, a unique platform with high-growth markets. Knight is involved in therapeutic areas such as oncology, hematology, infectious diseases, and other specialties.

Exelon, its top prescription product, is for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer’s and Parkinson’s disease. If you invest today, the share price is $5.12 (-1.16% year to date).

High risk. Tremendous reward

The profitability of biopharmaceutical companies depends mainly on the successful results of clinical trials and the proven effectiveness or safety of their lead drug candidates. From an investment perspective, the risks are high, but the potential rewards could be tremendous.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Investing

Canadian dollars are printed
Dividend Stocks

Beat the TSX With This Cash-Gushing Dividend Stock

Toronto-Dominion Bank (TSX:TD) stock could do well in the year ahead.

Read more »

monthly desk calendar
Dividend Stocks

Monthly Income: Top Dividend Stocks to Buy in November

Here are two of the best monthly dividend stocks in Canada you can buy in November 2024 and hold for…

Read more »

hand stacks coins
Investing

A Top TSX Stock to Buy Now for Real Wealth Later

Intact Financial (TSX:IFC) stock is a fantastic dividend-growth play for the next 15 years and beyond.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Thursday, November 14

The U.S. wholesale inflation data and Fed chair Jerome Powell’s remarks about the economy will remain on TSX investors’ radar…

Read more »

Man data analyze
Tech Stocks

3 Reasons Celestica Stock Is a Screaming Buy Now

These three reasons make Celestica stock a screaming buy for long-term investors.

Read more »

profit rises over time
Dividend Stocks

These 2 Dow Stocks Are Set to Soar in 2025 and Beyond

Two Dow Jones stocks are screaming buys but Canadians must hold them in an RRSP or RRIF to avoid paying…

Read more »

TFSA (Tax free savings account) acronym on wooden cubes on the background of stacks of coins
Dividend Stocks

How to Use Your TFSA to Earn Ultimate Passive Income

If you have a TFSA, then you have the key to creating ultimate passive income. All you need is a…

Read more »

Confused person shrugging
Dividend Stocks

Better Buy: Fortis Stock or Hydro One Stock?

Let's do a compare and contrast of these two top utilities stocks right now, shall we?

Read more »